IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Six of 10 analysts rate IDEXX Laboratories a buy, while four recommend holding the stock. The average 12-month price target is $747, well above its reported opening price of $518.39.
• IDEXX exceeded quarterly expectations, reporting $4.27 in EPS versus the $3.94 consensus and $1.22 billion in revenue versus $1.20 billion expected. Revenue increased 9.7% year over year, and the company provided fiscal 2026 EPS guidance of $14.69–$14.94.
• The stock has a $40.84 billion market capitalization and trades at a P/E ratio of 36.46, while institutional investors own 87.84% of outstanding shares. Recent analyst actions were mixed, including higher targets from UBS and Citigroup but a reduced target from Barclays.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $747.00.

A number of equities research analysts have recently commented on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. UBS Group boosted their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Citigroup raised their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a report on Wednesday, August 5th. Finally, Barclays reduced their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $518.39 on Monday. The company's fifty day moving average is $543.61 and its 200-day moving average is $555.14. The stock has a market cap of $40.84 billion, a price-to-earnings ratio of 36.46, a P/E/G ratio of 2.77 and a beta of 1.55. IDEXX Laboratories has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts predict that IDEXX Laboratories will post 14.81 EPS for the current year.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares of the company's stock, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in IDXX. J. Stern & Co. LLP increased its position in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $628,223,000. Arrowstreet Capital Limited Partnership grew its stake in shares of IDEXX Laboratories by 197.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 550,368 shares of the company's stock valued at $372,340,000 after buying an additional 365,274 shares in the last quarter. Alyeska Investment Group L.P. grew its position in shares of IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company's stock valued at $211,146,000 after acquiring an additional 197,808 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its position in IDEXX Laboratories by 93.4% during the first quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company's stock worth $186,707,000 after buying an additional 165,188 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.